Healio15d
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Medscape1y
Anti-cancer drugs
Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance ... with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer ...
The Sun4d
Daily pill which doubles survival for UK’s biggest cancer killler to be made routinely available on the NHS
The EGFR protein controls cell growth, and its mutation is common in NSCLC, causing abnormal growth. NICE says osimertinib targets EGFR-mutated cells to help prevent cancer from returning after ...
Pharmabiz25d
European Commission approves Janssen-Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC
This approval by the European Commission offers the potential to broaden first-line ... resistance and improve survival outcomes. “This approval marks significant progress for those living with the ...
Hosted on MSN11mon
Janssen seeks EMA approval of RYBREVANT for NSCLC
The asset is intended to be used along with lazertinib for the first-line treatment ... has immune cell-directing activity. It acts on tumours with activating and resistance EGFR mutations ...